Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.
Ferté
C
C
SITEP (Phase I Unit), Department of Medical Oncology, Institut Gustave Roussy, Villejuif; General Oncology Department, Centre Oscar Lambret, Lille.
Besse
B
B
Department of Medical Oncology, Institut Gustave Roussy, Villejuif.
Dansin
E
E
General Oncology Department, Centre Oscar Lambret, Lille.
Parent
F
F
Department of Pneumology, Antoine Beclere Hospital, Assistance Publique-Hopitaux de Paris, Clamart.
Buisine
M-P
MP
Molecular Biology Laboratory (Oncology Unit), Centre Hospitalier Universitaire Régional, Lille.
Copin
M-C
MC
Department of Pathology, CHRU, Lille, France.
Penel
N
N
General Oncology Department, Centre Oscar Lambret, Lille.
Soria
J-C
JC
SITEP (Phase I Unit), Department of Medical Oncology, Institut Gustave Roussy, Villejuif. Electronic address: soria@igr.fr.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009154:Mutation / Q000502:physiology; D009362:Neoplasm Metastasis; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D011799:Quinazolines / Q000627:therapeutic use*; D012074:Remission Induction; D013997:Time Factors; D018631:ras Proteins / Q000235:genetics*
D000970:Antineoplastic Agents; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins